This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Stock Mailbag: Amarin, Spectrum, Arena

Stocks in this article: AMRN SPPI ARNA CELG ALTH

Updated with additional information on Spectrum Pharmaceuticals (second item.)

BOSTON ( TheStreet) -- Happy new year! The Biotech Stock Mailbag enters its sixth year. Thanks for coming along for the ride.

Before I get to your emails and tweets, a housekeeping item: I'm holding a special biotech stock live chat on Monday, Jan. 9, at 7:30 p.m. ET. Note the evening time slot. I'll be in San Francisco all next week reporting from the J.P. Morgan Healthcare Conference so I hope to share with you some of the good, insidery-type stuff I learn at the biotech investors' meeting. Please join me and bring your biotech investing questions. Here's a preview of the J.P. Morgan conference.

Via Twitter, @mikeyc2113 asks, "Do you buy Amarin (AMRN) here?"

I never offer specific investment advice but let me tell you about a conversation I had this week with a health-care hedge fund manager -- a biotech investing pro who I've known and trusted for a long time. This investor is even more cynical than I am. He loves to short biotech stocks, so I took special notice when he told me that he just started buying Amarin.

On Tuesday night, Amarin announced a debt offering of $150 million. Before the Wednesday open, my investor friend dumped his brand new $500,000 position in Amarin.

This fund manager started buying Amarin because his research made him comfortable that the FDA would ultimately grant New Chemical Entity (NCE) to the lipid-lowering drug AMR101. He also believed Amarin would eventually win longer intellectual patent protection for AMR101, which makes it a potential billion-dollar blockbuster (if marketed by a competent Big Pharma partner).

Amarin doesn't need to raise more money before AMR101's approval decision date so when the company announced this debt offering Tuesday, my fund manager source drew up the following hypothesis to explain the deal:

1. Amarin's management team is so delusional and stupid to actually think they could achieve, through marketing themselves, anything more than a small fraction of the annual sales and market penetration that a large pharmaceutical company could.

2. Management, in their heart of hearts, realize No. 1, so the convertible offering represents a blatant misunderstanding of the financial markets and disregard for shareholder value. The debt offering is effectively a secondary at $8.81 per share if things go well with the downside of debt if things go poorly -- all merely as a hedge on the chance that they actually end up pursuing No. 1.

1 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs